US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

26.63

-0.1700-0.63%

Volume:14.99K

Turnover:396.66K

Market Cap:59.78M

PE:- -

High:27.02

Open:26.43

Low:26.29

Close:26.80

52wk High:27.02

52wk Low:15.63

Shares:2.24M

Float Shares:2.24M

Volume Ratio:0.40

T/O Rate:0.67%

Dividend:1.70

Dividend Rate:6.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Alkermes (ALKS)

Samsara Stock And 2 Founder Led Software Picks With Real Revenue Growth

Simply Wall St.

COMPASS Pathways PLC put volume heavy and directionally bearish

GSK’s ALANIS Trial: Fresh Momentum in AL Amyloidosis Could Reshape Investor Views

On Holding Stock And 2 Founder Led Picks Investors Are Watching Closely

Simply Wall St.

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires Live

Relmada Therapeutics Schedules Q2 2026 Financial Results Call

Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

Simply Wall St.

Compass Pathways Reports Post-hoc Analysis Showing Comp360 Trial Support Distinct from Psychotherapy

Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?

Simply Wall St.

Veradermics announces results from Phase 2 trial of VDPHL01

Alkermes Schedules Second-quarter Results Call and Webcast

Alkermes to Report Second Quarter Financial Results on July 28, 2026

THOMSON REUTERS

Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)

Alkermes Plc : TD Cowen Raises Target Price to $57 from $50

THOMSON REUTERS

Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), NovoCure (NVCR) and Bristol-Myers Squibb (BMY)

Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4

Alkermes Price Target Announced at $60.00/share by JP Morgan

Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis

Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/PSIL/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":26.63,"timestamp":1787767312167,"preClose":26.8,"halted":0,"volume":14992,"delay":0,"changeRate":-0.006343283582089616,"floatShares":2244976,"shares":2244976,"eps":0,"marketStatus":"Trading","change":-0.17,"latestTime":"08-26 14:04:06 EDT","open":26.429,"high":27.0175,"low":26.29,"amount":396664.78256,"amplitude":0.027146,"askPrice":26.77,"askSize":1000,"bidPrice":26.23,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787774400000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":26.8,"sharesOutstanding":1184976,"nav":25.732,"aum":57766911.89,"dividendRate":0.064022,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":26.9,"preClose":26.8,"latestTime":"08:45 EDT","volume":844,"amount":22607.829632,"timestamp":1787748339359,"change":0.1,"changeRate":0.003731,"amplitude":0.033955},"postHourTrading":{"tag":"盘后","latestPrice":26.88,"preClose":26.8,"latestTime":"19:32 EDT","volume":216,"amount":5804.83,"timestamp":1787700759051,"change":0.08,"changeRate":0.002985,"amplitude":0.002985},"volumeRatio":0.402609,"impliedVol":0.4011,"impliedVolPercentile":0.7251},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2244976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.402609,"shares":2244976,"dividePrice":1.7049,"high":27.0175,"amplitude":0.027146,"preClose":26.8,"low":26.29,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":26.63,"committee":-0.818182,"eps":0,"divideRate":0.064022,"volume":14992,"delay":0,"ttmEps":0,"open":26.429,"prevYearClose":17.17,"prevWeekClose":25.86,"prevMonthClose":23.5,"prevQuarterClose":24.05,"fiveDayClose":26.24,"twentyDayClose":23.23,"sixtyDayClose":21.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652329784","title":"Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Alkermes (ALKS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2652329784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652329784?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:30","pubTimestamp":1784543447,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Harmony Biosciences Holdings (HRMY) and Alkermes (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harmony-biosciences-holdings-hrmy-and-alkermes-alks-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-harmony-biosciences-holdings-hrmy-and-alkermes-alks-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","PSIL","BK4585","BK4137","IBRN","LABU","LU0029874061.USD","HCSG","BK4007","BK4588","ALKS","PSCH","XBI","BK4139","HRMY","XLV","FBT","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652576256","title":"Samsara Stock And 2 Founder Led Software Picks With Real Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2652576256","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652576256?lang=en_us&edition=fundamental","pubTime":"2026-07-19 11:34","pubTimestamp":1784432079,"startTime":"0","endTime":"0","summary":"Founder led companies can offer something many investors value in a world of shifting inflation data, mixed growth signals, and frequent policy surprises: leaders whose own reputations and long term vision are closely tied to shareholder outcomes. With global rates, energy costs, and consumer demand all pulling markets in different directions, backing founders who remain deeply invested in their business can be one way to focus on execution rather than headlines. This article highlights 3...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-iot/samsara/news/samsara-stock-and-2-founder-led-software-picks-with-real-rev","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-iot/samsara/news/samsara-stock-and-2-founder-led-software-picks-with-real-rev","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","SG9999015978.USD","BK1191","BK4613","PSIL","IE00BYV24P56.USD","IE00BMCWC346.EUR","LU2488822045.USD","IE00BGHQDM52.EUR","BK4539","BK4023","BK1593","IOT.AU","SG9999015952.SGD","BK4007","00867","SG9999015945.SGD","SG9999015986.USD","IE00BVYPNP33.GBP","IOT","SG9999004220.SGD","IE00BVYPNQ40.USD","GHRS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652287680","title":"COMPASS Pathways PLC put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2652287680","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652287680?lang=en_us&edition=fundamental","pubTime":"2026-07-18 02:15","pubTimestamp":1784312110,"startTime":"0","endTime":"0","summary":"Bearish flow noted in COMPASS Pathways (CMPS) PLC with 1,774 puts trading, or 3x expected. Most active are Nov-26 10 puts and Jul-26 13 calls, with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-plc-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-plc-put-volume-heavy-and-directionally-bearish-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652840282","title":"GSK’s ALANIS Trial: Fresh Momentum in AL Amyloidosis Could Reshape Investor Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2652840282","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652840282?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:32","pubTimestamp":1784305947,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. The ALANIS study from GlaxoSmithKline (GSK) is a Phase 2 trial testing ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-alanis-trial-fresh-momentum-in-al-amyloidosis-could-reshape-investor-views?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-alanis-trial-fresh-momentum-in-al-amyloidosis-could-reshape-investor-views?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1169590202.USD","BK4585","LU1829250122.USD","PSIL","BBC","IE0034390439.USD","IE00B19Z6F94.USD","GSKH","AL","GSK","BK4572","BK4588","BK4007","LU1169589451.USD","GSK.UK","BK4532","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652328229","title":"On Holding Stock And 2 Founder Led Picks Investors Are Watching Closely","url":"https://stock-news.laohu8.com/highlight/detail?id=2652328229","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652328229?lang=en_us&edition=fundamental","pubTime":"2026-07-17 23:28","pubTimestamp":1784302133,"startTime":"0","endTime":"0","summary":"Founder led companies can be especially interesting when inflation, rates, energy costs, and growth momentum are all pulling markets in different directions. With central banks weighing inflation data, bond markets reacting to policy expectations, and sectors responding differently to trade, energy, and housing trends, many investors are looking for leaders who are deeply aligned with long term outcomes. This article focuses on that theme by using a founder led screener built around personal...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4121000-choice1-main-header/1585186790255","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4121000-choice1-main-header/1585186790255"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/on-holding-stock-and-2-founder-led-picks-investors-are-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/on-holding-stock-and-2-founder-led-picks-investors-are-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1593","SG9999015952.SGD","LU1804176565.USD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","BK1191","BK4007","SG9999015945.SGD","GHRS","IE00BVYPNQ40.USD","SG9999015986.USD","LU0057025933.USD","IE00BGHQDM52.EUR","LU0511384066.AUD","00867","BK4585","BK4146","LU2488822045.USD","ISBC","BK4547","SG9999004220.SGD","ONON","BK4588","LU0289961442.SGD","LU0472753341.HKD","IE00BMCWC346.EUR","PSIL","LU2265009873.SGD","LU0289739343.SGD","SG9999015978.USD","BK4539","LU0069063385.USD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651423936","title":"European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2651423936","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651423936?lang=en_us&edition=fundamental","pubTime":"2026-07-16 23:16","pubTimestamp":1784214983,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were slightly lower on Thursday morning, down 0.07% to 1,911.26 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk  and drink and brewing company Anheuser-Busch Inbev , which rose 1.9% and 0.9% respectivelyThey were followed by pharmaceutical company Novartis , which added 0.8%.The decliners from continental Europe were led by tech companies Nokia  and Ericsson , which fell 7.8% and 1.8% respectively.They were followed by bank Santander , which shed 1.5%.From the UK and Ireland, the gainers were led by advertising and PR agency WPP  and telecom giant Vodafone , which rose 3.8% and 3% respectively. They were followed by beverage company Diageo , which added 2.5%.The decliners from the UK and Ireland were led by semiconductor company Arm  and pharmaceutical company Compass Pathways , which lost 6.9% and 2.1% respectively.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","GSIB","LU0320765489.SGD","BK4158","IE00B4R5TH58.HKD","LNOK","LU0208291251.USD","IE00BJT1NW94.SGD","LU0266013472.USD","PSIL","BK4559","ARMW","QQQA","LU0211331839.USD","LU1093756168.USD","BK4554","IE0002141913.USD","BK4521","SPRX","BK4141","THNR","BUD","BK4207","BK4007","BK4591","BK4532","DGE.UK","BK4139","LU2543165471.USD","IE00BJJMRZ35.SGD","NVO","LU0006061336.USD","ERIC","NOK","NVOH","NVOX","LU1232071149.USD","ARM","IE00B2B36J28.USD","ARMU","BK4543","OZEM","BK4609","SAN","BK4020","LU0154236417.USD","CMPS","BK4547","WPP","IE00BMPRXQ63.HKD","BK4578","TRFK","IE00BMPRXN33.USD","BK4515","DEO","IE00BFTCPJ56.SGD","BK4169","LU0348723411.USD","MEDX","PPH","BK4132","LU0070302665.USD","LU1093756325.SGD","BK4009","NVS","BK4599","IE0009355771.USD","ARMG","IE00BMPRXR70.SGD","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","AIPI","LU0081259029.USD","VOD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651469984","title":"Relmada Therapeutics Schedules Q2 2026 Financial Results Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2651469984","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651469984?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:05","pubTimestamp":1784199911,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics schedules Q2 2026 financial results callRelmada Therapeutics schedules a Q2 2026 results conference call on Aug. 6, 2026, at 4:30 p.m. ET.Webcast at https://viavid.webcasts.com/st","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL5pKfpR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","BK4007","SG9999014005.SGD","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014039.USD","PSIL","NDAQ","BK4112","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449806","title":"Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449806","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449806?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:58","pubTimestamp":1784199515,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at NRx Pharmaceuticals...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrxp/nrx-pharmaceuticals/news/market-sentiment-around-loss-making-nrx-pharmaceuticals-inc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrxp/nrx-pharmaceuticals/news/market-sentiment-around-loss-making-nrx-pharmaceuticals-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ONEQ","QDTE","NQmain","QQQY","PSQ","IYW","QQQE","MNQmain","QQQJ","TQQQ","QQQ","QID","NVIW.SI",".IXIC","TECS","QQQM","TQQY","QQQA","NRXP","GPIQ","BK4007","NDX","QLD","QYLG","SQQQ","PSIL","FTEC","JEPQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651445615","title":"Compass Pathways Reports Post-hoc Analysis Showing Comp360 Trial Support Distinct from Psychotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2651445615","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651445615?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:35","pubTimestamp":1784198118,"startTime":"0","endTime":"0","summary":"Compass Pathways reports post-hoc analysis showing COMP360 trial support distinct from psychotherapyCompass Pathways reported a published post-hoc analysis of an open-label Phase 2 PTSD study of COMP3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDLbRw9fg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651495333","title":"Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2651495333","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651495333?lang=en_us&edition=fundamental","pubTime":"2026-07-16 02:29","pubTimestamp":1784140192,"startTime":"0","endTime":"0","summary":"Earlier this month, COMPASS Pathways reported 26-week Phase 3 COMP006 data showing its COMP360 psilocybin candidate delivered rapid, durable symptom improvement and a generally well-tolerated safety profile in nearly 600 people with highly chronic treatment-resistant depression.\nThese results, combined with an ongoing rolling New Drug Application and a more supportive FDA stance on psychedelic medicines, could meaningfully reduce regulatory uncertainty around COMP360’s potential path to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/should-comp360s-durable-phase-3-results-and-fda-momentum-req","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/should-comp360s-durable-phase-3-results-and-fda-momentum-req","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSIL","BK4139","CMPS","BK4588","BK4585","BK4211","ISBC","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651745716","title":"Veradermics announces results from Phase 2 trial of VDPHL01","url":"https://stock-news.laohu8.com/highlight/detail?id=2651745716","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651745716?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:10","pubTimestamp":1784113852,"startTime":"0","endTime":"0","summary":"Veradermics (MANE) announced positive topline results from its open-label Phase 2 clinical trial evaluating VDPHL01, a proprietary extended-release...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veradermics-announces-results-from-phase-2-trial-of-vdphl01-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veradermics-announces-results-from-phase-2-trial-of-vdphl01-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","HYLG","BBC","MANE","MEDX","PSIL","GDOC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651948609","title":"Alkermes Schedules Second-quarter Results Call and Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2651948609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651948609?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:00","pubTimestamp":1784059224,"startTime":"0","endTime":"0","summary":"Alkermes schedules second-quarter results call and webcastAlkermes schedules a conference call and webcast at 8 a.m. ET on July 28, 2026 to discuss second-quarter financial results.Webcast player and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nNDL4ZHnfJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","PSCH","IBRN","BK4139","ALKS","PSIL","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651248620","title":"Alkermes to Report Second Quarter Financial Results on July 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651248620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651248620?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:00","pubTimestamp":1784059200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nTUA9LS4JH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","PSIL","ALKS","FBT","IBRN","PSCH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651143954","title":"Analysts Conflicted on These Healthcare Names: Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651143954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651143954?lang=en_us&edition=fundamental","pubTime":"2026-07-14 00:10","pubTimestamp":1783959019,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alkermes (ALKS), TransMedics Group (TMDX) and Praxis Precision Me...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-transmedics-group-tmdx-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-alkermes-alks-transmedics-group-tmdx-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LABU","XLV","BK4139","IE0002141913.USD","IBRN","IE00B4R5TH58.HKD","LU2324357040.USD","TMDX","BK4585","BK4082","LU0889565916.HKD","PSCH","XBI","LU0029874061.USD","LU0128526141.USD","FBT","BK4581","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","PRAX","IE00B2B36J28.USD","LU2065731478.USD","BK4588","PSIL","IE00BJT1NW94.SGD","ALKS","LU0109394709.USD","HCSG","MEDX","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651128211","title":"Alkermes Plc : TD Cowen Raises Target Price to $57 from $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2651128211","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651128211?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:29","pubTimestamp":1783949398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43F0V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSIL","MEDX","ALKS","IBRN","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651811463","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), NovoCure (NVCR) and Bristol-Myers Squibb (BMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651811463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651811463?lang=en_us&edition=fundamental","pubTime":"2026-07-13 21:00","pubTimestamp":1783947641,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on COMPASS Pathways (CMPS), NovoCure (NVCR) and Brist...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-compass-pathways-cmps-novocure-nvcr-and-bristol-myers-squibb-bmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-compass-pathways-cmps-novocure-nvcr-and-bristol-myers-squibb-bmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4534","LU1261432733.SGD","LU1585245621.USD","LU0306806265.USD","LU0237698245.USD","LU1868837136.USD","LU0882574055.USD","LU1093756168.USD","XBI","LU0321505868.SGD","IE00BJJMRZ35.SGD","CMPS","LU2242646821.SGD","IE0002141913.USD","LU1670711040.USD","BK4581","LU0029874061.USD","BK4082","LU0061475181.USD","IE00BSNM7G36.USD","HCSG","LU0267386448.USD","LU0096364046.USD","LU1670711123.USD","LU1868837300.USD","LU1670710661.SGD","BK4548","BMY","BK4585","LU0225771236.USD","PSIL","IE00B2B36J28.USD","BK4139","LU2125154935.USD","LU1868836914.USD","LU0128526141.USD","LU0868494617.USD","LU1291159041.SGD","LU1670710588.SGD","LU0114720955.EUR","IE00BJT1NW94.SGD","XLV","LU1032466523.USD","LU1323610961.USD","IHE","LU1430594728.SGD","LU0306807586.USD","NVCR","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111408","title":"Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111408","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111408?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:40","pubTimestamp":1783946412,"startTime":"0","endTime":"0","summary":"Based on recent positive 12-week data from Part D of the CIRRUS-HCM Phase 2 trial of EDG-7500, which included safety, echocardiographic, biomarker,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-expects-to-initiate-phase-3-trial-of-edg-7500-in-q4-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/edgewise-therapeutics-expects-to-initiate-phase-3-trial-of-edg-7500-in-q4-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EWTX","BBC","BK4539","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115701","title":"Alkermes Price Target Announced at $60.00/share by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115701","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115701?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:10","pubTimestamp":1783941000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALKS/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 07:10 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALKS","MEDX","IBRN","BK4139","PSIL","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651115250","title":"Alkermes Says Alixorexton Sustains Wakefulness Gains in Nine-month Narcolepsy Extension Study Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2651115250","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651115250?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:01","pubTimestamp":1783940468,"startTime":"0","endTime":"0","summary":"Alkermes says alixorexton sustains wakefulness gains in nine-month narcolepsy extension study interim analysisAlkermes reported interim long-term extension results showing alixorexton sustained clinic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL7r2w61:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","ALKS","PSCH","BK4139","MEDX","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651904115","title":"Alkermes - Alixorexton Generally Well Tolerated at All Doses Tested","url":"https://stock-news.laohu8.com/highlight/detail?id=2651904115","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651904115?lang=en_us&edition=fundamental","pubTime":"2026-07-13 19:00","pubTimestamp":1783940428,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nFWN43D02G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","IBRN","ALKS","PSCH","BK4139","MEDX","FBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}